DENVER, Oct. 07, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and information, reports that Kraig Biocraft Laboratories (OTCQB: KBLB), the undisputed global leader in the development and commercialization of spider silk, achieved a milestone in biotechnology: the successful mass production of spider silk using silkworms, solving a challenge that has eluded scientists and engineers for decades. For years, researchers have ...

ANN ARBOR, Mich., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, today announced the successful completion of its first simultaneous production cycle across two independent rearing centers. This milestone verifies the Company's multi-facility production model designed to increase throughput, enhance supply chain resilience, and establish the foundation for continuous recombinant spider silk production ...

DENVER, Sept. 24, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and information, reports that Kraig Biocraft Laboratories (OTCQB: KBLB), the undisputed global leader in the development and commercialization of spider silk, is positioning itself at the forefront of a new frontier in sportswear innovation as it prepares to reconvene its recombinant spider silk production program. Kraig Labs plans on delivering the first spid ...

Core Insights - Kraig Biocraft Laboratories, Inc. is pursuing the acquisition of an additional silkworm rearing center as part of its multi-facility expansion strategy to enhance the production of recombinant spider silk [1][3] Group 1: Company Developments - The company has achieved significant production growth and operational advancements over the last 18 months, particularly under the leadership of Dr. Nirmal Kumar, a leading expert in sericulture [2][4] - Kraig Labs relocated its headquarters to Asia's traditional silk-producing regions, resulting in record production volumes and streamlined processes [2][3] - The company aims to create a production network designed for continuous rearing cycles, greater reliability, and significant capacity increases to meet rising global demand [3][5] Group 2: Leadership and Strategy - Dr. Kumar's expertise is crucial for guiding the buildout and integration of the new facility, ensuring consistency and efficiency in large-scale operations [4] - The company's expansion efforts are aligned with its long-term vision to supply affordable, high-quality spider silk as a sustainable material solution [5]

Core Viewpoint - Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by officers and directors of Twist Bioscience Corporation, alleging that insiders made materially false statements and failed to disclose adverse facts about the company's business and operations [1] Group 1 - The investigation is based on a federal securities lawsuit claiming that insiders at Twist Bioscience overstated the commercial viability of the company's synthetic DNA manufacturing technology [1] - The lawsuit also alleges that the company engaged in accounting fraud and used unsustainable pricing strategies to inflate its financial condition and prospects [1]

撰文丨王聪 编辑丨王多鱼 排版丨水成文 电影《 阿凡达 》曾向我们展现了一个梦幻般的世界——进入夜晚，各种植物和动物都会发出绚烂的荧光。实际上，地球上也有着能够发光的生物，包括萤火虫、 水母、蘑菇，以及细菌，但它们在我们的生活中并不常见，而且，自然界中没有能够发光的植物。 自 1980 年代末以来，培育发光植物的想法一直吸引着科学家们的兴趣。当时，研究人员首次通过将萤火虫荧光素酶基因转入了烟草中，培育出了首株生物发光 植物 （需要荧光素激发） 。这项研究为去年在美国上市的第一款 转基因发光观赏植物 奠定了基础——一家名为 Light Bio 的公司推出了一种基因工程改造的植 物—— 萤火虫 矮牵牛花 （Firefly Petunias） ，将来自发光蘑菇的荧光素酶基因转入矮牵牛，该荧光素酶以咖啡酸为底物，而陆地植物能够自行产生咖啡酸，因 此，该植物无需特殊光照，也无需添加额外物质，就能在晚上持续发出绿色荧光。 萤火虫 矮牵牛花，售价为 29 美元 萤火虫 矮牵牛花，是 基因工程发光植物亮度方面的重大突破。然而，其亮度仍然相对较低，且发光颜色范围有限，这使其仅能用于室内观赏和装饰。 而现在，来自 华南农业大学 ...

Core Insights - Kraig Biocraft Laboratories, Inc. has fully operationalized its second production rearing center in Southeast Asia, enhancing its spider silk technology capabilities [1][5] - The establishment of two active production facilities allows for continuous rearing cycles of specialized recombinant spider silk silkworms, increasing resilience and scalability [2][5] - The company has expanded its breeding program with new genetic lines, which are expected to improve production efficiencies [3][5] Production and Operations - The dual-site capacity is designed to avoid past bottlenecks and create efficient redundancy, marking a significant advancement in sustained production [4][5] - Active teams are working with established parental lines for BAM-1 production hybrids and three additional parental lines introduced earlier this summer [3][5] Strategic Goals - The operational milestone of the second rearing center strengthens the foundation of the company's spider silk production platform, essential for scaling production and meeting market demand [5] - The company aims to diversify its breeding program and accelerate the development of next-generation hybrids to cater to growing demand from various markets and industries [5]

Company Analysis - Twist Bioscience's Q3 results were relatively soft, indicating a potential moderation in growth in the coming quarters due to macroeconomic uncertainty and concerns around academic funding [1] - The company is increasing its focus on achieving profitability, which may impact its growth trajectory [1] Industry Insights - Narweena, an asset manager, focuses on identifying market dislocations caused by a poor understanding of long-term business prospects, aiming for excess risk-adjusted returns [2] - The asset manager emphasizes the importance of secular growth opportunities in markets with barriers to entry, suggesting a high risk appetite and a long-term investment horizon [2] - The aging population, low population growth, and stagnating productivity growth are expected to create a different set of investment opportunities compared to the past, with some industries facing stagnation or secular decline [2] - There is a trend towards asset-light businesses, leading to a declining need for infrastructure investments, which is driving up asset prices and compressing risk premia over time [2]

Core Insights - Kraig Biocraft Laboratories, Inc. has successfully completed the first rearing cycles for three new recombinant spider silk production strains, demonstrating strong performance across key production metrics [1][2][3] - The transition from R&D to field production marks a critical milestone in the company's strategy to deploy advanced spider silk genetics rapidly [2][3] - The company is focused on expanding egg inventories and preparing for a second rearing cycle, indicating a robust production roadmap [3][4] Group 1 - The new strains have shown excellent vitality and alignment with large-scale production targets, validating the company's development pipeline [2][3] - The successful launch of these strains serves as proof of concept for future generations of advanced transgenic silks currently under development [3][4] - The company aims to build a cost-effective and scalable spider silk production platform, setting the stage for deploying advanced technologies with confidence [4] Group 2 - Kraig Labs is aggressively ramping up egg multiplication efforts to support the next generation of production cycles [3] - The company is recognized as a leader in genetically engineered spider silk-based fiber technologies, with significant implications for the global textile industry [6]

Core Insights - Kraig Biocraft Laboratories, Inc. is finalizing a significant three-year collaborative agreement with a key government agency in Southeast Asia to enhance its recombinant spider silk manufacturing platform [1][2] - The agreement is expected to be signed before the end of July and aims to accelerate the company's growth by providing access to new rearing facilities and technical resources [2][5] - The collaboration will enable Kraig Labs to optimize and expand spider silk production, unlocking new production capacity for its hybridized silkworm operations [3][4] Group 1 - The agreement includes provisions for creating parallel rearing operations to mitigate production risk and eliminate single points of failure [4] - By distributing parent strain and egg production across multiple facilities, the company aims to secure its supply chain and increase throughput capacity [4][5] - The COO of the company emphasized that this collaboration is a transformative step towards commercializing sustainable spider silk, providing strategic infrastructure and institutional support [5] Group 2 - Work under this agreement is anticipated to begin in August and will serve as a foundational element of the company's global spider silk manufacturing strategy [5] - The collaboration highlights the growing confidence in the company's pioneering biomaterials and its potential impact on the global textile industry [7]